Hematologic Disorders
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
Visual and Auditory Distraction for the Relief of Pain and Anxiety
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device